First Huda, Now Morphe Faces Proposed Nationwide Class Action Over Eyeshadow Colors
A class action in California federal court targets Morphe Cosmetics for the sale and marketing of eyeshadows containing unapproved colors for eye-area use that three consumers say inflicted physical injury. They seek to represent consumers nationwide, citing breach of warranties, negligence, false advertising, and other claims.
You may also be interested in...
US consumers who purchased Neon Obsession pressed pigment palettes may be entitled to refunds under a settlement preliminarily approved in California’s Central District. Plaintiffs say Huda promoted Neon Obsession as eyeshadow despite use of color additives not approved by the FDA for eye-area use, an issue that cannot be cured by a “buried” disclaimer on product packaging.
Morphe Holdings has taken a new name, strengthened its leadership team and announced two new brand additions to its growing, multi-category beauty portfolio. Meanwhile, Lauder is partnering with Atropos Therapeutics to discover senomodulators with potential anti-aging benefits, and Fragrance Creators Association again successfully prevents tariffs on essential oil imports from the EU.
The House Appropriations Committee asks the US Food and Drug Administration to provide a report to Congress in two years on the resources it would need to develop a database for fragrance allergens used in cosmetics. The committee’s report accompanying FY2023 FDA funding legislation also touches on OTC sunscreen regulation, PFAS in cosmetics, skin-lightening ingredients, and more.